Raksha Das

Raksha Das

Auto-generated profile, based on publicly available information

Raksha Das

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
MRManon Ragonnet-Cronin
Manon Ragonnet-Cronin
RNRungtiwa Nutalai
Rungtiwa Nutalai
JHJiandong Huo
Jiandong Huo
ADAiste Dijokaite-Guraliuc
Aiste Dijokaite-Guraliuc
RDRaksha Das
Raksha Das
SRSakib Rokadiya
Sakib Rokadiya
Summary: Some COVID-19 patients are unable to clear their infection or are at risk of severe disease, requiring treatment with neutralising monoclonal antibodies (nmAb) and/or antivirals. The rapid roll-out of novel therapeutics means there is limited understanding of the likely genetic barrier to drug resistance. Unprecedented genomic surveillance of SARS-CoV-2 in the UK has enabled a genome-first approach to the detection of emerging drug resistance. Here we report the accrual of mutations in Delta and Omicron cases treated with casirivimab+imdevimab and sotrovimab respectively. Mutations occur within the epitopes of the respective nmAbs. For casirivimab+imdevimab these are present on contiguous raw reads, simultaneously affecting both components. Using surface plasmon resonance and pseudoviral neutralisation assays we demonstrate these mutations reduce or completely abrogate antibody affinity and neutralising activity, suggesting they are driven by immune evasion. In addition, we show that some mutations also reduce the neutralising activity of vaccine-induced serum.